Results 1 to 10 of about 42,464 (273)

Sildenafil provokes headache but not migraine in men with migraine without aura: a randomized, placebo-controlled crossover trial [PDF]

The Journal of Headache and Pain
Background Cyclic guanosine monophosphate (cGMP)-mediated mechanisms plays a role in migraine pathophysiology. Sildenafil, a phosphodiesterase type 5 inhibitor, increases intracellular cGMP and can reliably induce migraine attacks in women.
Anas Mohammad, Ditte Bork Iversen, Nete Lundager Klokker Rausgaard, Christina Kruuse, Dagmar Beier, Tore Bjerregaard Stage, Lanfranco Pellesi   +6 more
doaj   +2 more sources

Endophenotype-based in silico network medicine discovery combined with insurance record data mining identifies sildenafil as a candidate drug for Alzheimer’s disease

Nature Aging, 2021
Jiansong Fang, Pengyue Zhang, Lang Li
exaly   +2 more sources

Bioequivalence study of a new sildenafil 100 mg orodispersible film compared to the conventional film-coated 100 mg tablet administered to healthy male volunteers

Drug Design, Development and Therapy, 2017
Milko Radicioni,1 Chiara Castiglioni,1 Andrea Giori,2 Irma Cupone,3 Valeria Frangione,4 Stefano Rovati4 1CROSS Research S.A., Phase I Unit, Arzo, Switzerland; 2IBSA Farmaceutici Italia, Lodi, Italy; 3Bouty S.p.A., Strada Padana Superiore, Cassina De ...
Radicioni M, Castiglioni C, Giori A, Cupone I, Frangione V, Rovati S   +5 more
doaj   +2 more sources

Sildenafil Citrate Therapy for Pulmonary Arterial Hypertension

New England Journal of Medicine, 2005
Ardeschir Ghofrani, Adam Torbicki, Lewis J Rubin   +2 more
exaly   +2 more sources

PDE5 inhibitors – pharmacology and clinical applications 20 years after sildenafil discovery

British Journal of Pharmacology, 2018

exaly   +2 more sources

Sildenafil Can Affect Innate and Adaptive Immune System in Both Experimental Animals and Patients

Journal of Immunology Research, 2017
Sildenafil, a type 5 phosphodiesterase inhibitor (PDE5-I), is primarily used for treating erectile dysfunction. Sildenafil inhibits the degradation of cyclic guanosine monophosphate (cGMP) by competing with cGMP for binding site of PDE5.
Monika Kniotek, Agnieszka Boguska
doaj   +2 more sources

Sildenafil effect on testosterone-induced prostate hypertrophy and relaxation of urinary bladder neck muscles [PDF]

Toxicology Reports
Background: Previous studies have demonstrated the expression of phosphodiesterase-5 receptors in prostate tissue. In this study, we investigated the efficacy of sildenafil citrate in testosterone-induced benign prostate hyperplasia (BPH) in rabbits ...
Qasim A. El-Dwairi, Karem H. Alzoubi, Rania Mahafdeh   +2 more
doaj   +2 more sources

A real‐world pharmacovigilance study of FDA adverse event reporting system events for sildenafil

Andrology, 2023
Sildenafil, a selective inhibitor of phosphodiesterase type 5 (PDE5), is widely used for the treatment of erectile dysfunction (ED). However, the safety profile of sildenafil, including adverse event (AEs), requires comprehensive evaluation.
Y. Wang, Bin Zhao, Haiyan Yang, Zheng Wan   +3 more
semanticscholar   +1 more source

Preparation and physicochemical characterization of sildenafil cocrystals

Journal of Advanced Pharmaceutical Technology & Research, 2021
Sildenafil is a specific inhibitor of the phosphodiesterase type 5 (PDE-5) enzyme that protects cyclic guanosine monophosphate from breakdown by PDE-5. It is a biopharmaceutical categorization system Class II medication with low bioavailability because ...
Somchai Sawatdee, Apichart Atipairin, Supitchaya Rakkummerd, Onsinee Suriyaphol, David J Harding, Poowadon Muenraya, Phimphaka Harding   +6 more
doaj   +1 more source

Effects of sildenafil on symptoms and exercise capacity for heart failure with reduced ejection fraction and pulmonary hypertension (the SilHF study): a randomized placebo‐controlled multicentre trial

European Journal of Heart Failure, 2022
Pulmonary hypertension (PHT) may complicate heart failure with reduced ejection fraction (HFrEF) and is associated with a substantial symptom burden and poor prognosis. Sildenafil, a phosphodiesterase‐5 (PDE‐5) inhibitor, might have beneficial effects on
Trond J. Cooper, J. Cleland, M. Guazzi, P. Pellicori, T. Ben Gal, O. Amir, A. Al-Mohammad, A. Clark, A. McConnachie, K. Steine, K. Dickstein   +10 more
semanticscholar   +1 more source